Another nice PR this week. Chemdex to Provide Genome Therapeutics With Complete Procurement Solution For Life Sciences. 12 Leading Biotechnology Companies Also Select Chemdex Procurement Solution
PALO ALTO, Calif., Sept. 14 /PRNewswire/ -- Chemdex(TM) Corporation (Nasdaq: CMDX), the leading provider of
business-to-business electronic commerce solutions for the life sciences industry, today announced that Genome Therapeutics
Corporation (Nasdaq: GENE), a leader in the field of genomics research, has selected Chemdex as its procurement solution for
laboratory supplies. Using Chemdex, researchers and lab technicians at Genome Therapeutics will source, compare and
purchase supplies directly from their desktops, allowing them to spend more time conducting scientific research.
In addition to Genome Therapeutics, Chemdex also announced that 12 leading biotechnology companies have selected
Chemdex as their life science procurement solution. These include Arbor Vita Corporation, Calydon Inc., CV Therapeutics,
Inc., Eos Biotechnology, Inc., ImmunoGen, Inc., Inspire Pharmaceuticals, Inc., Maxygen, Inc., MitoKor, Ontogeny, Inc.,
Protein Delivery Inc., Protein Sciences Corp. and Telik, Inc.
"Genome Therapeutics selected Chemdex in order to streamline the purchasing process and to reduce the vast amounts of
paperwork that buying lab supplies has required up to this point," said Kurt Hentschel, Manager of Operational Services at
Genome Therapeutics. "As one of the nationally-funded centers of the Human Genome Project, cost control and quality
standards are of the utmost importance to our Company. Chemdex understands the needs of our scientists and allows us to
meet our goals of obtaining high quality products in a cost-effective and highly efficient manner."
Chemdex hosted solutions are easily configured to the business rules of the buying company, making Chemdex the fastest way
to implement a fully-featured procurement solution. The Chemdex system delivers the streamlined processes and cost savings
necessary for economic success in today's competitive world of life science research and development.
"Chemdex is the industry leader in offering comprehensive web-based purchasing solutions for laboratory supply," said David
Perry, president, CEO and co-founder of Chemdex. "Working with GTC and other top biotechnology companies reflects
Chemdex's commitment to providing our customers with powerful procurement at a reasonable cost of ownership."
About Genome Therapeutic Corporation
Genome Therapeutics Corporation is a leader in the field of genomics -- the identification and functional characterization of
genes. The Company's commercial gene discovery strategy is to identify and characterize human genes associated with major
diseases and elucidate bacterial genes responsible for many serious infectious diseases. Together with its strategic partners,
Genome Therapeutics is using genomic information to develop a new generation of pharmaceuticals. The Company's
non-exclusive PathoGenome(TM) Database is the most comprehensive source of microbial organism sequence information
available.
About Chemdex
Chemdex Corporation is the leading provider of business-to-business electronic commerce solutions for the life sciences
industry. Chemdex provides the only complete e-commerce solution consisting of an extensive online marketplace with
biological and chemical reagents, lab supplies, instruments and equipment; hosted procurement, tailored to the unique business
requirements of each customer; and comprehensive services and support. Uniting enterprises, buyers and suppliers, Chemdex
solutions streamline business processes, enhance productivity and reduce costs. Chemdex customers include pharmaceutical
and biotechnology companies, as well as academic institutions. For more information, visit Chemdex at www.chemdex.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding
Chemdex's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Risk
factors and other details are described in the company's Registration Statement on Form S-1 and in the company's other filings
with the Securities and Exchange Commission.
SOURCE: Chemdex Corporation
CONTACT: Amy McKnight, 415-512-0770, or mcknight@schwartz-pr.com, or Dina Butin, 415-512-0770, or dinab@schwartz-pr.com,
both of Schwartz Communications, Inc., for Chemdex Corp.; or Marsha Dillon of Chemdex Corporation, 650-813-0300, ext. 261, or
mdillon@chemdex.com |
